key: cord-0717688-3qnh484m
authors: Tangen, Jorun; Aukrust, Pål; Barratt-Due, Andreas; Skulstad, Helge; Edvardsen, Thor
title: Reduced cardiac function by echocardiography in a minority of COVID-19 patients three months after hospitalization
date: 2021-11-07
journal: J Am Soc Echocardiogr
DOI: 10.1016/j.echo.2021.10.014
sha: 3c9c8817622d3a2731537b9865bceac78374558e
doc_id: 717688
cord_uid: 3qnh484m

nan

The COVID-19 patients were 59±13 years, (69% male). Twenty-five percent had hypertension, 16% had diabetes, and 16% had chronic heart disease prior to COVID-19.

≥53%. In the COVID-19 patients as a whole, LVGLS was reduced compared to the control group (-18.6±2.2% vs -20.1±2.0%, p=0.001), but only 14 patients experienced LVGLS > -17%.

Of these, eight patients had LV hypertrophy, including four with known hypertension. In the six remaining patients, reduced LVGLS could not be attributed to hypertrophic or any other known premorbid cardiac diseases. Table 1 .

After three months, 12 patients (13%) had elevated high-sensitivity cardiac troponin (HScTn) (>99% percentile), but only one of these had decreased LVGLS.

In summary, our prospective study showed normal LV function by LVEF in all patients three months after hospitalization for COVID-19. LVGLS, however, was reduced in 15% of the patients. Furthermore, we could not find any relationships between reduced GLS and disease severity (treatment at ICU) or elevated HScTn after three months. The majority of the patients with reduced GLS had arterial hypertension prior to COVID-19 infection, this might explain the impaired LV function, but we cannot exclude that this was caused by COVID-19. Cardiac function might potentially be influenced by the antiviral medications, but we could not find such effect. Our study was, however, not originally designed for this purpose.

The number of patients is small and increases the risk of both type I and type II statistical errors. Another limitation is lack of comparison with echocardiographic examination during hospitalization. Our study underscores the need for more studies on long-term cardiovascular consequences after COVID-19.

J o u r n a l P r e -p r o o f 

Indications for and Findings on Transthoracic Echocardiography in COVID-19

Persisting Adverse Ventricular Remodeling in COVID-19 Survivors: A Longitudinal Echocardiographic Study

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging